<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Contact Us Select Models
Select Models
Champions Oncology_AACR2025 Poster 3903_Cairo_FINAL_06Apr2025.pdf

Poster

AACR 2025 Poster

Multi-omics and histological assessment to identify patient-derived xenograft models of invasive lobular carcinoma &nbsp; &nbsp;

Summary

Invasive lobular carcinoma (ILC), the second most common subtype of breast cancer, is underrepresented in research due to the scarcity of relevant preclinical models. Characterized by loss of E-cadherin (CDH1), ILC exhibits distinct biological behavior compared to invasive ductal carcinoma (NST), yet most available PDX models derive from the latter. A lack of ILC-specific models has limited the development of targeted therapies.

In collaboration with the University of Pittsburgh, Champions Oncology leveraged the Lumin® platform to perform multi-omics and pathology-based characterization of breast cancer PDX models to identify and validate ILC-specific models.

  • By integrating genomic (WES, RNA-seq) and clinical data from 128 breast cancer models, researchers identified 7 putative ILC models based on CDH1 mutations, low E-cadherin expression, and histopathological reclassification.

  • Molecular analysis revealed enrichment of luminal PAM50 subtypes and recurrent alterations in genes such as PIK3CA, FOXA1, PTEN, and CDH1 in ILC models—offering insight into subtype-specific oncogenic pathways.

  • Pathological validation, including immunohistochemistry for E-cadherin, p120, ER, PR, and HER2, confirmed the ILC phenotype in selected models, establishing a robust framework for future ILC research and preclinical drug testing.

Download the poster